MADRIGAL PHARMACEUTICALS, INC.
Ticker: 1157601
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY2026 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 |
|---|---|---|---|---|---|---|
| INCOME | ||||||
| Revenue | 311.34+8.4% | 287.27+35.0% | 212.80+55.0% | 137.25+120.7% | 62.18+324.7% | 14.64 |
| Total Income | 311.34+8.4% | 287.27+35.0% | 212.80+55.0% | 137.25+120.7% | 62.18+324.7% | 14.64 |
| EXPENSES | ||||||
| Expenditure | 404.06+0.7% | 401.24+54.3% | 260.00+20.1% | 216.56+21.3% | 178.48+0.7% | 177.18 |
| PROFIT | ||||||
| Net Profit | -94.39+17.3% | -114.19-170.1% | -42.28+42.3% | -73.24+31.5% | -106.96+29.6% | -151.97 |
| KEY METRICS | ||||||
| OPM % | -29.78%+9.89pp | -39.67%-17.49pp | -22.18%+35.61pp | -57.79%+42.21pp | -100.00% | -100.00% |
| NPM % | -30.32%+9.43pp | -39.75%-19.88pp | -19.87%+33.49pp | -53.36%+46.64pp | -100.00% | -100.00% |
| EPS | -3.25+36.0% | -5.08-167.4% | -1.90+42.8% | -3.32+32.5% | -4.92+30.7% | -7.10 |
Corporate Events
Board MeetingMDGL
202616Jun
Board Meeting
Stockholders approved 2026 Stock and Employee Stock Purchase…
SEC Filing ↗ Board MeetingMDGL
202622Apr
Board Meeting
Board Reclassification – Julian C. Baker and Daniel J. Brenn…
SEC Filing ↗